Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-9,213
Closed -$842K 182
2023
Q2
$842K Sell
9,213
-518
-5% -$42.5K 0.09% 102
2023
Q1
$716K Sell
9,731
-585
-6% -$50.6K 0.08% 113
2022
Q4
$862K Sell
10,316
-385
-4% -$34.7K 0.1% 99
2022
Q3
$1.04M Buy
10,701
+78
+0.7% +$9.3K 0.13% 88
2022
Q2
$1.12M Buy
10,623
+590
+6% +$75.4K 0.13% 94
2022
Q1
$1.73M Buy
10,033
+1,062
+12% +$159K 0.19% 74
2021
Q4
$1.45M Buy
8,971
+2,980
+50% +$479K 0.17% 82
2021
Q3
$893K Buy
5,991
+329
+6% +$68.4K 0.11% 95
2021
Q2
$1.39M Buy
5,662
+1,091
+24% +$286K 0.18% 75
2021
Q1
$1.21M Buy
4,571
+83
+2% +$23.4K 0.17% 80
2020
Q4
$1.32M Buy
4,488
+21
+0.5% +$5.38K 0.2% 71
2020
Q3
$1.06M Buy
4,467
+146
+3% +$33.2K 0.19% 75
2020
Q2
$858K Sell
4,321
-15
-0.3% -$2.8K 0.16% 81
2020
Q1
$796K Buy
4,336
+37
+0.9% +$6.58K 0.17% 71
2019
Q4
$718K Buy
4,299
+104
+2% +$15.5K 0.13% 86
2019
Q3
$550K Buy
4,195
+264
+7% +$34.4K 0.1% 98
2019
Q2
$477K Buy
+3,931
New +$467K 0.11% 103

Other funds holding AMED

Bell Bank's AMED Position: Q3 2023 in Review

Bell Bank sold out of Amedisys (AMED) in Q3 2023, closing a stake of 9,213 shares — an estimated $842K sold.

Bell Bank first reported a position in AMED in Q2 2019 and held it in 17 quarters. The position peaked at $1.73M in Q1 2022. 286 funds tracked by Wall St. Rank hold AMED as of Q3 2023.

  • Bell Bank reported no remaining Amedisys position as of Q3 2023 after selling out during the quarter.
  • Bell Bank sold 9,213 Amedisys shares in Q3 2023, an estimated $842K.
  • Bell Bank first reported a position in Amedisys in Q2 2019 and held it in 17 quarters.
  • Bell Bank's Amedisys position peaked at $1.73M in Q1 2022.
  • 286 funds tracked by Wall St. Rank held Amedisys as of Q3 2023.

Based on Bell Bank's 13F filing for Q3 2023, filed 30 Oct 2023.